Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash & Current Investments (2016 - 2025)

Rockwell Medical's Cash & Current Investments history spans 16 years, with the latest figure at $25.0 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 15.72% year-over-year to $25.0 million; the TTM value through Dec 2025 reached $25.0 million, up 15.72%, while the annual FY2025 figure was $25.0 million, 15.72% up from the prior year.
  • Cash & Current Investments reached $25.0 million in Q4 2025 per RMTI's latest filing, up from $23.7 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $46.1 million in Q1 2021 to a low of $8.6 million in Q1 2024.
  • Average Cash & Current Investments over 5 years is $21.6 million, with a median of $20.0 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: plummeted 78.51% in 2022, then skyrocketed 101.08% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $22.4 million in 2021, then fell by 4.22% to $21.5 million in 2022, then tumbled by 49.12% to $10.9 million in 2023, then soared by 97.55% to $21.6 million in 2024, then grew by 15.72% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for RMTI's Cash & Current Investments are $25.0 million (Q4 2025), $23.7 million (Q3 2025), and $18.4 million (Q2 2025).